Next-Generation HIV therapies Market

Next-Generation HIV therapies Market - Global Assessment 2021 - 2031, Industry Analysis 2016 - 2020 and Opportunity

Next-Generation HIV therapies Market Segmented By Integrase Inhibitors, Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Combination HIV Medicines drug type in Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Industry: Healthcare

Format: PPT*, PDF, EXCEL

Delivery Timelines: Contact Sales

Report Type: Ongoing

Report Price

$ 4900*

Pre Book
Request Report Sample

Report ID: PMRREP32900

Next-Generation HIV therapies Market: Overview

Next-Generation HIV therapies Market is said to grow in the given forecast period. According to World health organization, in 2020, 37.7 million people in the world were infected with HIV. More that 73% of them had undergone ART treatment. 16% of all the population didn’t know that they were suffering from HIV.

This has led the market to take hike. Government has been initiating awareness amongst the people to have themselves tested, funding, pharmaceuticals industries be innovating drugs that no longer be resistant to the infected person. Technological advancements have been in demand. These are the factors that can augment the growth of the next generation HIV therapies market.

What is Driving Demand for Next-Generation HIV therapies Market?

Adoption in advanced drug combinations by major players has been increased in the biotechnology and pharmaceuticals industries has caused a rapid growth in global HIV drug market. Bringing in new technologies and innovation leads to advancement in biological process.

Government indulging themselves into spreading the word of awareness amongst the people has been the driving factor for the demand. Increase in the cases of HIV/ AIDS has again augmented the market growth.

The large patient pool has been demanding new long acting drugs with less frequency of consumptions have been driving the market. WHO reports increase in the HIV patient across different regions that leads to increase in the drug market.

U.S. Next-Generation HIV Therapies Market Outlook

According to CDC, in 2019, U.S. reported on an average of 1,189,700 million people of 13 years of age and above suffered from HIV infection. In addition, 13% of them was totally aware of the infection. U.S. has been the dominating region in leading chronic diseases count.

The rise in aging population has been demanding the new methodologies in the treatment of HIV infection. In 2020, ViiV Healthcare announced US FDA approval for its Rukobia (fostemsavir), 600 mg extended-release tablets. Merck Sharp & Dohme Corp, in 2019 got approved by US FDA for DELSTRIGO and PIFELTRO combination drugs. NIH is also funding the research institutes for the drug developments.

Europe Next-Generation HIV Therapies Market Outlook

Europe, is the second largest region to boost the demand for the HIV Therapies market.  The presence of many HIV Drug industries in this regions has made the market to grow at a significant rate. According to EU, HIV remains the most communicable disease in the Europe region.

Furthermore, the constant collaboration amongst each other has been driving the demand market. For instance, in 2020, Theratechnologies Europe Limited, collaborated with Loxxess for distribution of TROGARZO, an ART in Europe region.

The increase in disease prevalence has been demanding the HIV therapies market. The demand is significantly because of the rise of government funding, technological innovations, and well established healthcare infrastructure.

Global Next-Generation HIV Therapies Market Key Players

  • ViiV Healthcare
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck Sharp & Dohme Corp.
  • Bristol-Myers Squibb Company
  • Janssen Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • AbbVie Inc.
  • Genentech, Inc.
  • Mylan N.V.
  • Other Prominent Players

Key Segments:

By Drug Type

  • Integrase Inhibitors
  • Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Combination HIV Medicines
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Region

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East and Africa

Key Points:

  • Define, depict and figure Bioreactors item market by type, quality, order, and area.
  • Provide systems for organizations to manage the effect of COVID19.
  • Provide market-dynamic investigation, including market driving components, market improvement limitations.
  • Provide market passage procedure investigation for new players or players who are prepared to enter the market, including market portion definition, customer examination, circulation model, item informing and situating, and value methodology investigation.
  • Keep up with global market drifts and give an examination of the effect of the COVID-19 pandemic on significant areas of the world.
  • Analyze the market chances of partners and give market pioneers subtleties of the well-known picture.

To know more about delivery timeline for this report Contact Sales

Companies Covered in This Report

Thank you for taking time to visit our website, click like if you found the information on this page useful?

This site uses cookies, including third-party cookies, that help us to provide and improve our services.
Google translate